Education
About Us
Working with TipRanks
Follow Us
Salarius Pharmaceuticals (SLRX)
:SLRX
RESEARCH TOOLSreports
SLRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.45 - $7.20
Previous CloseN/A
Volume13.28K
Average Volume (3M)2.36M
Market Cap
$2.11M
Enterprise Value$13.90M
Total Cash (Recent Filing)$1.80M
Total Debt (Recent Filing)$112.23K
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding2,127,286
10 Day Avg. Volume7,014,915
30 Day Avg. Volume2,360,848
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.50
Price to Sales (P/S)0.00
P/FCF Ratio-1.36
Enterprise Value/Market Cap6.60
Enterprise Value/Revenue388.37
Enterprise Value/Gross Profit-12.57K
Enterprise Value/Ebitda-0.80
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Salarius Pharmaceuticals News
PremiumCompany Announcements
Salarius Pharmaceuticals Granted Nasdaq Compliance Extension
Options Prices
Currently, No data available
---
Ownership Overview
2.84%
Insiders
0.45% Mutual Funds
0.72% Other Institutional Investors
98.57% Public Companies and
Individual Investors
SLRX FAQ
What was Salarius Pharmaceuticals’s price range in the past 12 months?
Salarius Pharmaceuticals lowest stock price was $0.45 and its highest was $7.20 in the past 12 months.
What is Salarius Pharmaceuticals’s market cap?
Salarius Pharmaceuticals’s market cap is $2.11M.
When is Salarius Pharmaceuticals’s upcoming earnings report date?
Salarius Pharmaceuticals’s upcoming earnings report date is Aug 06, 2025 which is in 35 days.
How were Salarius Pharmaceuticals’s earnings last quarter?
Salarius Pharmaceuticals released its earnings results on May 08, 2025. The company reported -$1.027 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.027.
Is Salarius Pharmaceuticals overvalued?
According to Wall Street analysts Salarius Pharmaceuticals’s price is currently Overvalued.
Does Salarius Pharmaceuticals pay dividends?
Salarius Pharmaceuticals does not currently pay dividends.
What is Salarius Pharmaceuticals’s EPS estimate?
Salarius Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Salarius Pharmaceuticals have?
Salarius Pharmaceuticals has 2,127,286 shares outstanding.
What happened to Salarius Pharmaceuticals’s price movement after its last earnings report?
Salarius Pharmaceuticals reported an EPS of -$1.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 9.859%.
Which hedge fund is a major shareholder of Salarius Pharmaceuticals?
Currently, no hedge funds are holding shares in SLRX
Company Description
Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Technical Analysis
Aptevo Therapeutics
―
ReShape Lifesciences
―
Virpax Pharmaceuticals
―
Protagenic Therapeutics
―
ZyVersa Therapeutics
―